Humira Biosimilars: A Two-Year Update 

Since 1961, NERA has provided unparalleled guidance on the most important market, legal, and regulatory questions of the day. Our work has shaped industries and policy around the world. Our field-leading experts and deep experience allow us to provide rigorous analysis, reliable expert testimony, and data-powered policy recommendations for the world’s leading law firms and corporations as well as regulators and governments. Our experience, integrity, and economic ingenuity mean you can depend on us in the face of your biggest economic and financial challenges.

Explore Firm Details

The loss of exclusivity for Humira and the entry of biosimilars into the US market have driven major shifts in biologics, most notably a sharp decline in pricing.

United States Food, Drugs, Healthcare, Life Sciences

David Blackburn,Chris Stomberg, PhD, and Rasmus Jørgensen

Your Author LinkedIn Connections

Article Insights

NERA are most popular:

within Food, Drugs, Healthcare, Life Sciences, Real Estate and Construction and Consumer Protection topic(s)

The loss of exclusivity for Humira and the entry of biosimilars into the US market have driven major shifts in biologics, most notably a sharp decline in pricing. Drawing on two years of market data, this paper shows Humira's estimated net price per prescription fell by more than 50% between 2022 and 2024.

Authored by Managing Directors David Blackburn and Chris Stomberg, and Director Rasmus Jørgensen, the analysis explores trends in pricing, prescription volumes, and biosimilar uptake. It also examines broader implications for manufacturers, payers, and healthcare providers as the market continues to adjust to expanded biosimilar availability.

To download publication, please click here

Originally published 11 December 2025.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Authors